Neena Bitritto-Garg analyst DEUTSCHE BANK

Currently out of the existing stock ratings of Neena Bitritto-Garg, 31 are a HOLD (21.09%), 110 are a BUY (74.83%), 6 are a SELL (4.08%).

Neena Bitritto-Garg

Work Performance Price Targets & Ratings Chart

Analyst Neena Bitritto-Garg, currently employed at DEUTSCHE BANK, carries an average stock price target met ratio of 47.11% that have a potential upside of 34.44% achieved within 177 days.

Neena Bitritto-Garg’s has documented 275 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 11-Feb-2025.

Wall Street Analyst Neena Bitritto-Garg

Analyst best performing recommendations are on SAGE (SAGE THERAPEUTIC).
The best stock recommendation documented was for ACAD (ACADIA PHARMACEUTICALS) at 12/12/2023. The price target of $25 was fulfilled within 1 day with a profit of $3.83 (18.09%) receiving and performance score of 180.92.

Average potential price target upside

ACAD ACADIA Pharmaceuticals KOD Kodiak Sciences NBIX Neurocrine Biosciences SAGE Sage Therapeutic ZGNX Zogenix LBPH Longboard Pharmaceuticals ALEC Alector AMLX Amylyx Pharmaceuticals CMPS Compass Pathways Plc KRTX Karuna Therapeutics PRTA Prothena plc ROIV Roivant Sciences Ltd SRPT Sarepta Therapeutics PASG Passage Bio ANAB AnaptysBio ARNA Arena Pharmaceuticals ATAI ATAI Life Sciences BV CRTX Cortexyme DBTX Decibel Therapeutics PRVL Prevail Therapeutics PEAR Pear Therapeutics DRTS Alpha Tau Medical Ltd LB L Brands SA Seabridge Gold ZGN Ermenegildo Zegna NV

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 21-Oct-2025

$40

$11.98 (42.76%)

$39

Buy Since 25-Sep-2025

$38

$9.98 (35.62%)

$29

Buy Since 17-Oct-2023

$49

$20.98 (74.88%)

$40

Buy Since 28-Feb-2024

$41

$12.98 (46.32%)

$29

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Neena Bitritto-Garg?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?